Terns Pharmaceuticals, Inc.
TERN
Rank in Stocks
#3590
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Share Price
$52.95
Last synced: 2026-05-15
Market Cap
$4.77B
Change (1 day)
0.00%
Change (1 year)
552.09%
Country
US
Trade Terns Pharmaceuticals, Inc. (TERN)
Category
Healthcare
Stock price history for Terns Pharmaceuticals, Inc. (TERN)
Highest end of day price: $52.95 on 2026-05-01
Lowest end of day price: $20.53 on 2021-02-01
Lowest end of day price: $20.53 on 2021-02-01
Stock price history of Terns Pharmaceuticals, Inc. from 2021 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -1.17% |
| 2025 | 517.55% |
| 2024 | -2.74% |
| 2023 | -12.48% |
| 2022 | 13.79% |
| 2021 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $514.04 | 20.59% |
US
|
|
| $241.53 | 778.61% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $814.41 | 16.18% |
CH
|
|
| $875.26 | 4.85% |
NL
|
